SCHEMBL3829650

SCHEMBL3829650

CNc1ccc(-c2[nH]c(-c3ccccc3/C=C/C(=O)OC)nc2-c2ccc(-n3ccnc3)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 1/20 0.39
▸ CCNC P24863 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ TEK Q02763 5/20 0.38
▸ ROCK1 Q13464 1/20 0.38
▸ HTT P42858 1/20 0.37
▸ PORCN Q9H237 6/20 0.37
▸ ALOX5 P09917 1/20 0.37
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ MGAM O43451 1/20 0.36
▸ PDE3B Q13370 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13679655 0.86 PTPN1 (0.46) RAF1HTTALOX5KDM4EPDE3B
SCHEMBL3824756 0.85 SELP (0.40) RAF1CCNCCDK8ROCK1HTT
SCHEMBL3824090 0.84 SELP (0.41) RAF1CCNCCDK8ROCK1HTT
SCHEMBL6608185 0.82 RAF1 (0.43) RAF1CCNCCDK8TEKALOX5
SCHEMBL3826599 0.79 MEN1 (0.37) RAF1CCNCCDK8TEKKDM4E
SCHEMBL22579360 0.70 MAOB (0.59) HTTPORCNCYP3A4CYP2D6KDM4E
SCHEMBL13780575 0.69 MAPT (0.47) HTTKDM4EMEN1KMT2A
SCHEMBL3824754 0.69 ALOX5 (0.41) ALOX5KDM4EPOLBMEN1KMT2A
SCHEMBL28869394 0.68 MAOB (0.63) HTTCYP3A4KDM4EPDE3BPDE3A
SCHEMBL22579332 0.65 ADH5 (0.59) HTTCYP3A4KDM4EPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0999835-B1 IMIDAZOLE DERIVATIVES AS MDR MODULATORS TAIJI BIOMEDICAL INC (US) 2009-09-09 — — EP disclosed
EP-2082740-A2 Use of imidazole derivatives as MDR modulators Taiji Biomedical, Inc. (US) 2009-07-29 — — EP disclosed
US-5840721-A INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS ONTOGEN CORPORATION (US) 1998-11-24 — — US disclosed
Send feedback